Entries |
Document | Title | Date |
20080200556 | Amine Compounds And Inhibiting Neurotrasmitter Reuptake - The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake. | 08-21-2008 |
20080200557 | Method for Inhibiting Lipid Peroxidation - The invention relates generally to the use of N-substituted dopamine derivatives for the treatment of diseases and disorders that involve abnormal lipid peroxidation. This method comprises the administration of a pharmaceutically effective amount of N-acetyldopamine derivatives or N-alkyldopamine derivatives and a pharmaceutically acceptable carrier for treating an animal or human suffering abnormal lipid peroxidation. The N-acetyldopamine derivative or N-alkyldopamine derivatives may be administered alone or in combination with N-acetylserotonin (NAS) to inhibit lipid peroxidation. | 08-21-2008 |
20080242733 | (-)-Pseudoephedrine as a sympathomimetic drug - The present invention provides pharmaceutical compositions which include (−)-pseudoephedrine and a pharmaceutically acceptable carrier, wherein the (−)-pseudoephedrine is substantially-free of (+)-pseudoephedrine. In another embodiment, the present invention provides methods of relieving nasal and bronchial congestion and of inducing pupil dilation which include administering a pharmaceutically effective amount of (−)-pseudoephedrine to a mammal. The (−)-pseudoephedrine used in the present methods is substantially free of (+)-pseudoephedrine and also substantially free of side effects caused by administration of (+)-pseudoephedrine. | 10-02-2008 |
20080269347 | EPINEPHRINE FORMULATIONS - The present invention generally concerns an epinephrine formulation that has enhanced stability. In particular embodiments, the formulation is an injectable formulation. In specific aspects, the formulation comprises epinephrine, EDTA, and one or more of an antioxidant such as cysteine, citric acid, acetylcysteine, or thioglycerol. The formulations are suitable for any medical condition that is in need of epinephrine, although in specific embodiments the medical condition is anaphylaxis, asthma, or cardiac arrest. | 10-30-2008 |
20080300316 | SUBSTITUTED PHENETHYLAMINES - Disclosed herein are substituted phenethylamine alpha adrenergic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 12-04-2008 |
20080306162 | Treatment of Inflammatory Disorders and Pain - A compound that is useful for the treatment or prevention of a condition such as pain, that is associated with T-cell proliferation or that is mediated by pro- and/or anti-inflammatory cytokines, is of formula (I) wherein R | 12-11-2008 |
20080312332 | G Protein-Coupled Receptor Antagonist and Its Use for Preventing and Treating Alzheimer's Disease - A method for screening a reagent for treating or preventing Alzheimer's disease or related neurological pathology includes the steps of: (a) activating a receptor and determining a first extent of endocytosis of the receptor, wherein the receptor is a G-protein coupled receptor that associates with presenilin-1; (b) activating the receptor under the same conditions as in step (a), in the presence of a candidate reagent, and determining a second extent of endocytosis of the receptor; (c) determining a difference between the first extent of endocytosis and the second extent of endocytosis; and (d) repeating steps (a)-(c), if the difference is less than a threshold. Uses of receptor antagonists for manufacturing medicaments for treating or preventing Alzheimer's disease or related neurological pathology, wherein the receptor antagonists inhibit endocytosis of a G-protein coupled receptor that associates with presenilin-1 during endocytosis. | 12-18-2008 |
20090005457 | Solid forms comprising (-)-O-desmethylvenlafaxine and uses thereof - Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising (−)—O-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders. | 01-01-2009 |
20090018208 | Novel Succinate Salt of O-Desmethyl-Venlafaxine - A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided. | 01-15-2009 |
20090076164 | DEUTERIUM-ENRICHED TAPENTADOL - The present application describes deuterium-enriched tapentadol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090082468 | DEUTERIUM-ENRICHED LEVALBUTEROL - The present application describes deuterium-enriched levalbuterol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090088482 | Compositions and Methods For Treating Heart Failure - The present invention provides compositions and methods for the following: preventing and treating heart failure; preventing heart failure in a patient with a pre-heart failure condition; treating and preventing heart failure with ischemic and non-ischemic causes; treating and preventing heart failure in a subject status post myocardial infarction; reversing damage to the heart following myocardial infarction; by administering to a subject an effective amount of an adrenergic beta-agonist either alone or in combination with an effective amount of an adrenergic beta-1 antagonist. FIG. | 04-02-2009 |
20090137686 | Treatment of Ophthalmic Diseases - Beta-amino alcohols are useful for the treatment of ophthalmic conditions. | 05-28-2009 |
20090143480 | Use of RR/SR-ractopamine - A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented. | 06-04-2009 |
20090156685 | (R)-CHIRAL HALOGENATED SUBSTITUTED FUSED HETEROCYCLIC AMINO COMPOUNDS USEFUL FOR INHIBITING CHOLESTEROL ESTER TRANSFER PROTEIN ACTIVITY - The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described. | 06-18-2009 |
20090186946 | Genetically Modified Animal and Use Thereof - The present invention provides a non-human mammal deficient in the expression of the SLC-1 gene, having the characteristics of (1) a lower blood insulin level in glucose tolerance test, (2) increased insulin sensitivity, (3) higher resistance to obesity even on high fat diet, (4) a smaller white fat cell size, and (5) accentuated lipolysis, compared with the corresponding wild-type animal, or a portion of the body thereof. Also provided is an obesity and/or type II diabetes model non-human mammal that is deficient in the expression of the SLC-1 gene, having the characteristics of (1) elevated expression of adiponectin, (2) delayed onset of hyperglycemia, (3) a lower blood glycohemoglobin level, and (4) accentuated energy consumption, compared with the corresponding obesity and/or type II diabetes model non-human mammal wherein the expression of the gene is normal, or a portion of the body thereof. | 07-23-2009 |
20090203798 | Solid Pharmaceutical Compositions Comprising a SIP Receptor Agonist and a Sugar Alcohol - A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol. | 08-13-2009 |
20090247643 | Medicinal herbal composition for treating infection - Herbal compositions derived from Kenyan plants are provided for the treatment of HIV and other infectious diseases. The herbal compositions can include the extracts of up to 14 plants, including the root of | 10-01-2009 |
20090306216 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain - A compound for therapeutic use, of the formula (I), wherein R | 12-10-2009 |
20090318562 | Use of Bupropion Metabolites for the Treatment of Inflammatory Disorders - Compounds that may be used for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro-inflammatory cytokines are of formula (1) | 12-24-2009 |
20090318563 | Nematicidal Compositions and Methods - Certain ethanolamine analogs and related compounds useful in the control of nematodes that infest plants or the situs of plants are described. Nematodes that parasitize animals can also be controlled using the methods and compounds of this invention | 12-24-2009 |
20100022655 | Therapeutic Agents For The Treatment Of Lymphoid Malignancies - Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject. | 01-28-2010 |
20100022656 | OPTICALLY ACTIVE PHENYLETHANOL AMINES AND PREPARING METHOD THEREOF - The invention provides compounds of formula (I) having (−) or (+) configuration, or pharmaceutically acceptable salts thereof, wherein R | 01-28-2010 |
20100022657 | Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine - 1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other disturbances and disorders of the gastrointestinal, as a pressor agent, as a nasal decongestant and in ophthalmology, at low does and without significant side effects. | 01-28-2010 |
20100029782 | Calcilytic Compounds - Novel calcilytic compounds of Formula (I), pharmaceutical compositions, methods of synthesis, and methods of using them are provided. | 02-04-2010 |
20100041766 | Medthods, Devices And Formulations For Targeted Endobronchial Therapy - The present invention provides an improved means of treating tracheobronchitis, bronchiectasis and pneumonia in the nosocomial patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airways distal of the ventilator circuit. The treatment means eliminates the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment means also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen. | 02-18-2010 |
20100081721 | TREATMENT OF SKIN AND MUCOSAL SUPERFICIAL WOUNDS USING ADRENERGIC RECEPTOR AGONISTS - The invention generally relates to the compositions and methods related to the use of adrenergic receptor agonists solutions for the treatment of skin and mucosal superficial wounds. Some of the preferred adrenergic receptor agonists include epinephrine, phenylephrine, norepinephrine, methoxamine, and mixtures thereof. The invention also relates to devices suitable for applying these solutions to the skin or the mucosal area. Methods according to the invention are especially effective to control superficial skin and mucosal bleeding and accelerate healing time. | 04-01-2010 |
20100160446 | 3,4-DIMETHOXYPHENETHYLAMINE MODULATORS OF L-TYPE CALCIUM CHANNEL - The present invention relates to new 3,4-dimethoxyphenethylamine modulators of L-type calcium channel activity, pharmaceutical compositions thereof, and methods of use thereof. | 06-24-2010 |
20100168245 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE - This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease. | 07-01-2010 |
20100168246 | AMINE COMPOUNDS AND INHIBITING NEUROTRANSMITTER REUPTAKE - The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake. | 07-01-2010 |
20100184865 | Use Of RR/SR-Ractopamine - A method of promoting weight loss in animals or humans by administering thereto a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. | 07-22-2010 |
20100240764 | Use of S-Clenbuterol - The use of S-Clenbuterol for restoring and/or maintaining the function of partially or completely damaged/degenerated cells in the central nervous system and/or other nerve cells is claimed. The use of S-Clenbuterol leads to activation of astrocytes and initiation of endogenous processes of neuroprotection, it thus being possible for the damage or destruction of nerve cells to be reduced and, in some cases, even prevented. | 09-23-2010 |
20100311841 | SYNTHETIC SPHINGOLIPID ANALOGS - Therapeutic compounds based on synthetic sphingolipid analogs are provided, particularly alkylthiophenyl substituted ceramide analogs, suitable for treating degenerative, infectious, and other diseases. | 12-09-2010 |
20100311842 | Use of 1-Phenyl-3-dimethylamino-propane Compounds for Treating Neuropathic Pain - Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy. | 12-09-2010 |
20110003897 | METHODS OF ENGINEERING POLAR DRUG PARTICLES WITH SURFACE-TRAPPED HYDROFLUOROALKANE-PHILES - Disclosed herein are polar drug particles with surface-trapped hydrofluoroalkane-philes and methods of making the same. | 01-06-2011 |
20110021636 | METHOD FOR CRYSTALLIZATION OF 2-AMINO-2-[2-[4-(3-BENZYLOXYPHENYLTHIO)-2-CHLOROPHENYL]-ETHYL]-1,3-PROPAN- EDIOL HYDROCHLORIDE - A method for highly efficiently preparing high purity crystals of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chloro-phenyl]-ethyl]-1,3-propanediol hydrochloride. The method involves dissolving 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol in a mixed solvent comprising a solvent in which its hydrochloride is highly soluble and a solvent in which its hydrochloride is less soluble, to prepare a solution of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol; and then adding hydrochloric acid to the resulting solution with stirring, to crystallize the hydrochloride of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chloro-phenyl]ethyl]-1,3-propanediol. | 01-27-2011 |
20110046231 | SOLID FORMS OF (.+-.)-O-DESMETHYLVENLAFAXINE SALTS - The present invention relates to solid forms of (±)-O-desmethylvenlafaxine salts, processes for preparation, pharmaceutical compositions, and method of treating thereof. More particularly, the present invention provides solid forms of acid addition salts of (±)-O-desmethylvenlafaxine wherein the acid counter ion is provided by an acid selected from the group consisting of oxalic acid, benzoic acid and lactic acid. | 02-24-2011 |
20110054038 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE - The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy/activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and/or released. | 03-03-2011 |
20110105620 | ORGANIC COMPOUNDS - A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol. | 05-05-2011 |
20110124739 | Use of Sphingosine-1-phosphate (S1P) Receptor Agonists for the Treatment of Brain Degenerative Diseases - Disclosed is the use of sphingosine-1-phosphate (S1P) receptor agonists, preferably 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, in the treatment of progressive dementia or brain degenerative diseases | 05-26-2011 |
20110130464 | Combination Agent for Improving Carcass Performance in Finishing Pigs - A composition of ractopamine and astaxanthin, included as additives in a feed, for finishing hogs, improves carcass performance. | 06-02-2011 |
20110144211 | USE OF MICROCRYSTALLINE CELLULOSE FOR INTERFERING WITH THE EXTRACTION OF EPHEDRINE - Use of microcrystalline cellulose and, optionally, a surfactant in an aqueous pharmaceutical composition in order to inhibit the extraction of ephedrine for the purpose of drug abuse. | 06-16-2011 |
20110152380 | Paediatric Compositions For Treating Multiple Sclerosis - The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C | 06-23-2011 |
20110166237 | Process for the Synthesis of Arformoterol - The present invention provides a process for preparing a compound of formula (VI) or a salt thereof, the process comprising: (i) reacting 4-methoxyphenyl acetone with an amine of formula (VIII) under conditions of reductive amination to produce a compound of formula (II) or a salt thereof, wherein there is no isolation of an imine intermediate formed during the reductive amination; (ii) condensing the compound (II) or the acid addition salt thereof with an α-haloketone of formula (III) to produce the compound of formula (IV); (iii) reducing the compound (IV) to a compound of formula (V); and (iv) reducing the compound (V) to the compound of formula (VI), wherein the reduction is carried out in the presence of either (1) a hydrogen donating compound in the presence of a hydrogen transfer catalyst; or (2) ammonium formate using a hydrogenation catalyst, wherein R | 07-07-2011 |
20110190398 | USE OF IMMUNOSUPPRESSANT COMPOUNDS IN A NEW INDICATION - A compound of formula V or formula VI for use in the treatment of a demyelinating peripheral neuropathy: wherein X is O, S, SO or SO | 08-04-2011 |
20110201691 | MODULATION OF FIBROBLAST ACTIVITY - The invention includes a method for simultaneously decreasing the amount of TGFβ1 and increasing the amount of TGFβ3 produced by a fibroblast, the method comprising contacting the fibroblast with an agent which positively modulates β2-adrenergic receptor; a method for reducing fibroblast differentiation, the method comprising contacting the fibroblast with an agent which positively modulates β2-adrenergic receptor; and a method of reducing the deposition of collagen in a subject, the method comprising administering to the subject an agent which positively modulates β2-adrenergic receptor. | 08-18-2011 |
20110237680 | CRYSTAL FORMS OF O-DESMETHYLVENLAFAXINE FUMARATE - Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical composition thereof. | 09-29-2011 |
20110237681 | INHALABLE EPINEPHRINE - The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action. | 09-29-2011 |
20110237682 | S1P RECEPTOR MODULATORS FOR TREATING MUTIPLE SCLEROSIS - The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula X | 09-29-2011 |
20110294897 | Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion - Methods for the treatment of patients suffering from dry eyes, by using adrenergic beta-receptor agonists, particularly salbutamol and in particular the optically pure or substantially pure R-enantiomer thereof. The embodiments disclosed herein include methods of increasing the Meibomian lipid secretion and thereby reducing or eliminating xerophthalmia symptoms by the administration of formulations containing therapeutically effective amounts of an adrenergic beta-receptor agonist to said patients. In particular, certain embodiments disclosed herein concern compositions that contain R-salbutamol as the active beta-receptor stimulating ingredient. In certain embodiments, the formulations are administered to the ocular surface of the eye and/or to the eyelid (the underside of the eyelid and/or the top of the eyelid) of a patient in need thereof. | 12-01-2011 |
20120065271 | METHOD OF ACCELERATING MUSCLE GROWTH, DECREASING FAT DEPOSITS AND IMPROVING FEED EFFICIENCY IN LIVESTOCK ANIMALS - A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed | 03-15-2012 |
20120101167 | Treatment of ocular and cerebral ischemia - Ocular and cerebral blood flow are enhanced by the administration of (−) erythro isomer of α-methyl epinephrine, a C | 04-26-2012 |
20120108670 | FORMOTEROL TARTRATE PROCESS AND POLYMORPH - A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph. | 05-03-2012 |
20120129943 | METHOD OF INCREASING OR MAINTAINING THE REPRODUCTIVE PERFORMANCE OF SOWS - The present invention relates to methods and feed compositions for increasing or maintaining the reproductive performance of sows. More particularly, the present invention relates to methods of increasing or maintaining the reproductive performance of sows by administering a biologically active compound during lactation, and food compositions comprising said biologically active compound for the purposes of increasing or maintaining the reproductive performance of sows. The present invention also relates to a method of increasing or maintaining ovarian function in sows. | 05-24-2012 |
20120129944 | STABILIZED COMPOSITION COMPRISING AT LEAST ONE ADRENERGIC COMPOUND - A stabilised composition comprising at least one adrenergic compound and at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite and a sulfite compound. | 05-24-2012 |
20120136063 | FTY720-DERIVED ANTICANCER AGENTS - A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula I: | 05-31-2012 |
20120136064 | METHODS FOR SCREENING TO IDENTIFY THERAPEUTIC AGENTS FOR ALZHEIMER'S DISEASE AND USE THEREOF - Methods for treating Alzheimer's Disease (AD) using modulators of lysosomal activity are described herein. More particularly, methods described herein relate to the use and application of compounds or agents that enhance lysosomal activity for the treatment of AD. In a particular aspect, the method relates to the use and application of compounds or agents that increase the pH of the lysosome and/or increase the overall activity of lysosomal proteases for the treatment of AD. Also described herein are methods and assays for screening to identify compounds or agents that increase the pH of the lysosome and/or increase the overall activity of lysosomal proteases for the treatment of AD. | 05-31-2012 |
20120157543 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE - This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease. | 06-21-2012 |
20120157544 | Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein - The present invention relates to a compound of formula A, wherein R is alkyl. | 06-21-2012 |
20120196938 | Beta 2 Adrenergic Receptor Agonists Such As Terbutaline for Use in the Treatment of Nocturnal Hypoglycemia - The invention is concerned with methods, regimens and dosage forms employing a beta 2 adrenergic receptor agonist such as terbutaline sulphate, for treating nocturnal hypoglycaemia in human subjects whilst reducing incidence of hyperglycaemia in said subjects upon wakening. | 08-02-2012 |
20120232158 | METHODS OF TREATING HYPERACIDIC DISORDERS - The present invention relates to methods for treating or preventing hyperacidic disorders such as GERD or NERD using calcium receptor active compounds. | 09-13-2012 |
20120283334 | Treatment of Viral Infections - The invention provides compositions, medicaments and methods of treatment of viral infections, especially respiratory disorders caused by viral infections. In particular, the invention relates to the treatment of acute viral infections using a range of related 1-phenyl-2-amino ethanol, ethanal, and ethane derivatives. | 11-08-2012 |
20120309840 | Treatment of Pain Associated with Trigeminal Neuralgia - The use of tapentadol for the treatment of pain associated with disorders of the trigeminal nerve, in particular for use in the treatment of pain associated with trigeminal neuralgia. | 12-06-2012 |
20120316246 | TOPICAL VASOCONSTRICTOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY - Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided. | 12-13-2012 |
20120322884 | EPINEPHRINE NANOPARTICLES, METHODS OF FABRICATION THEREOF, AND METHODS FOR USE THEREOF FOR TREATMENT OF CONDITIONS RESPONSIVE TO EPINEPHRINE - The invention provides a composition including epinephrine nanoparticles and methods for therapeutic use of the composition in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions. | 12-20-2012 |
20120329879 | BETA-ADRENERGIC RECEPTOR AGONISTS AND USES THEREOF - Provided herein are methods for improving function in a retinal cell associated with a diabetic condition and for treating a diabetic retinopathic condition in a subject. The methods comprise contacting the retinal cell or administering to the subject a beta-adrenergic receptor agonist or R-isomer thereof such as have the chemical structural formula: | 12-27-2012 |
20130072567 | TREATMENT OF FAECAL INCONTINENCE AND OTHER CONDITIONS WITH 1R, 2S-METHOXAMINE - 1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other disturbances and disorders of the gastro-intestinal, as a pressor agent, as a nasal decongestant and in ophthalmology, at low does and without significant side effects. | 03-21-2013 |
20130102682 | FINGOLIMOD IN THE FORM OF A SOLID SOLUTION - The invention relates to an intermediate containing fingolimod and matrix material, wherein the fingolimod is present in the matrix material in the form of a solid solution. The invention also relates to granules and pharmaceutical formulations containing fingolimod in the form of a solid solution in matrix material. The subject matter of the invention further relates to methods of preparing a solid solution of fingolimod or of an intermediate, and also granules and pharmaceutical formulations containing fingolimod in the form of a solid solution. | 04-25-2013 |
20130102683 | MELT-GRANULATED FINGOLIMOD - The invention relates to methods including the step of joint melt processing of (i) fingolimod or a pharmaceutically acceptable salt thereof, with (ii) a matrix former into an intermediate, intermediates obtainable in this way, and oral dosage forms, especially tablets, containing the intermediates of the invention. The invention further relates to a method of preparing the dosage forms of the invention, especially tablets. Finally, the invention relates to oral dosage forms for the treatment of multiple sclerosis. | 04-25-2013 |
20130123366 | Therapeutic Agents for the Treatment of Lymphoid Malignancies - Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject. | 05-16-2013 |
20130150454 | TARGETING OF T-LYMPHOCYTES TO TREAT AMYOTROPHIC LATERAL SCLEROSIS - Methods and therapeutic compositions are disclosed for treating neurodegenerative disorders and, in particular Amyotrophic Lateral Sclerosis, using sphingosine1-phosphate receptor modulators, such as fingolimod or a pharmaceutically acceptable salt, hydrate, or solvate thereof. | 06-13-2013 |
20130197096 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT - The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease. | 08-01-2013 |
20130203859 | METHODS OF TREATING ACNE - A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound. | 08-08-2013 |
20130237607 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN - The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta | 09-12-2013 |
20130253065 | Inhalable Epinephrine - The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action. | 09-26-2013 |
20130253066 | Use of an S1P Receptor Agonist - The present invention relates to new uses of S1P receptor modulator or agonist such as fingolimod, for reducing or delaying the progression of cerebral atrophy. | 09-26-2013 |
20130281540 | Method for the Subcutaneous Administration of Parenteral Medications - The invention presently disclosed is a method for the administration of parenteral medication to a person via subcutaneous delivery designed and intended to facilitate the quick, safe and effective administration of such medication, the method having implications in the treatment of a host of conditions and ailments. As conceived, the inventor contemplates the method having particularized utility in the administration of epinephrine to a person suffering from the life-threatening condition of anaphylaxis. | 10-24-2013 |
20130281541 | USE IN BRAIN DEGENERATIVE DISEASES - Disclosed is a new use for sphingosine-1-phosphate (S1P) receptor agonists in the treatment of progressive dementia or brain degenerative diseases. | 10-24-2013 |
20130289127 | AMINOALKANOL DERIVATIVES - Disclosed are compounds of formula I | 10-31-2013 |
20140011884 | USE OF S1P RECEPTOR MODULATOR - Use of an S1P receptor modulator in the treatment or prevention of a disease or condirion dependent on brain-derived neurotrophic factor (BDNF) expression. | 01-09-2014 |
20140011885 | Organic Compounds - A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol. | 01-09-2014 |
20140039063 | LEUKOTRIENES AND ASTHMA EXACERBATION RISK - The invention provides methods for predicting the risk for a subject of exacerbation of an inflammatory disease of the airways upon exposure to an environmental agent as well as methods for reducing a subject's risk of exacerbation of an inflammatory disease of the airways upon exposure to an environmental agent. | 02-06-2014 |
20140051766 | Organic Compounds - The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C | 02-20-2014 |
20140080916 | ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE - Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods for treatment, inhibition, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention. | 03-20-2014 |
20140094522 | COMPOUND FORMULATIONS OF 2-AMINO-1, 3-PROPANEDIOL COMPOUNDS - Pharmaceutical concentrate formulations comprising 2-amino-1,3-propanediol compounds, analogs thereof and salts thereof, particularly 2-amino-2-[2-(4-octylphenyl)ethyl]-propane-1,3-diol or a pharmaceutically acceptable salt thereof in an organic solvent or semi-aqueous solvent and methods for administration of the undiluted and diluted concentrate are provided. | 04-03-2014 |
20140142192 | Compositions Comprising Sphingosine 1 Phosphate (S1P) Receptor Modulators - The present invention relates to stable compositions comprising a sphingosine 1 phosphate (S1P) receptor modulator, suitable for use as a dosage form. The S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula Y. | 05-22-2014 |
20140187644 | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability - The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapone, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalevo200®. The invention also relates to processes for making such compositions. | 07-03-2014 |
20140187645 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE - This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease. | 07-03-2014 |
20140221498 | AMINO DIOL DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to amino diol derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 08-07-2014 |
20140256822 | TRANSMUCOSAL DRUG DELIVERY SYSTEM - Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from whence, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH. | 09-11-2014 |
20140343159 | FORMULATION OF SMALL ADRENERGIC AGONIST SALT FORMS IN ORGANIC SOLVENTS - Aspects of the present disclosure are directed to formulations that permit the solubilization and long term, stable storage of adrenergic agonist vasoconstrictors in organic solvents. Provided herein are formulations comprising about 250 mM to about 3000 mM of an acid salt of an adrenergic agonist vasoconstrictor dissolved in a pharmaceutically acceptable topical delivery vehicle comprising a water miscible, organic solvent having a water content of less than 40% by weight. Also provide are methods for using and kits containing such formulations. | 11-20-2014 |
20140371323 | FORMULATIONS COMPRISING 2-AMINO-2-[2-(4-OCTYLPHENYL)ETHYL]PROPANE-1,3-DIOL - A solid pharmaceutical composition suitable for oral administration, comprising:
| 12-18-2014 |
20150011644 | Methods and Compositions for Deterring Abuse - A therapeutic composition comprising: a methamphetamine precursor; a gel-forming polymer; an emulsifier with a lipid backbone; a disintegrant; and a surfactant; wherein the ratio of emulsifier to gel-forming polymer on a weight basis is between about 10:1 and 1:10. | 01-08-2015 |
20150087720 | Dosage Regimen of an S1P Receptor Agonist - S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial 3 to 6 days of treatment the daily dosage is raised so that in total the R-fold (R being the accumulation factor) standard daily dosage is administered and thereafter continued at the standard daily dosage or at a daily dosage lower than the standard daily dosage. | 03-26-2015 |
20150094378 | Inhalable Epinephrine - The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action. | 04-02-2015 |
20150133563 | METHODS AND COMPOSITIONS OF STABLE PHENYLEPHRINE FORMULATIONS - The invention is directed to methods and compositions of stabilizing phenylephrine formations. The composition has good time-dependent stability at low temperature and has no change in its outward appearance even after having been stored at least 6 months. | 05-14-2015 |
20150141520 | Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof - Stabilized pharmaceutical compositions comprising a S1P receptor modulator as an active agent(s), process of preparation and method of using the same are provided. The present invention also relates to stabilized pharmaceutical compositions comprising fingolimod, or pharmaceutically acceptable salts, esters, hydrates and solvates thereof, process of preparation and method of using the same. | 05-21-2015 |
20150335593 | Diversion - And/Or Abuse-Resistant Compositions And Methods For Making The Same - A composition formulated for diversion- and/or abuse-resistance, includes at least one active pharmaceutical ingredient (API), each present in an acidic form, a first compound capable of coupling to the acidic form of the API to form a complex, where the resulting complex is resistant to separation by conventional separation methods, and a second compound capable of preferentially coupling to the first compound to thereby release the API from the complex. | 11-26-2015 |
20150344958 | A SCREENING METHOD, A KIT, A METHOD OF TREATMENT AND A COMPOUND FOR USE IN A METHOD OF TREATMENT - A method of screening for a candidate compound for the treatment of a condition involving dysregulation of metabolism in a mammal, by bringing a compound into contact with cells that express a GPCR and that further express a GRK, determining whether the contacting causes a response of the GRK in cells brought into contact with the compound, determining whether the contacting causes a response of a classical secondary messenger in cells brought into contact with the compound; and identifying the candidate compound based on the determined GRK response and response of a classical secondary messenger in the cells. A kit for use in the method. A compound for use in the treatment of a condition involving dysregulation of metabolism in a mammal and a method of treatment of such a condition. | 12-03-2015 |
20150374832 | EPINEPHRINE FORMULATIONS FOR MEDICINAL PRODUCTS - The invention relates to compositions of epinephrine formulation in an aqueous solution that enhances the chemical stability of epinephrine and consequently extends the product shelf life. The formulation comprises epinephrine or a salt thereof, a tonicity modifier, and a complexing agent, in an aqueous solution adjusted to a pH of about 2-7. A process for manufacturing and methods of using the formulation for the medicinal products are also provided. | 12-31-2015 |
20160009636 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | 01-14-2016 |
20160051494 | MULTI-DOSE MEDICATION KIT FOR TREATING ANAPHYLAXIS - Various exemplary embodiments relate to an emergency medicament component. The multi-dose medication kit includes a first medication administration component including a first element having first dosage of epinephrine administered by intramuscular or subcutaneous administration. The multi-dose medication kit further includes second medication administration component including a second element, having a second dosage of a β-agonist provided in a dosage which is effective to treat symptoms of anaphylaxis. | 02-25-2016 |
20160058715 | PARENTERAL DOSAGE FORM OF NOREPINEPHRINE - The present invention relates to a ready-to-administer parenteral dosage form of norepinephrine which comprises an aqueous solution of norepinephrine, having an anti-oxidant which is not a sulfite anti-oxidant, wherein the dosage form is stable at room temperature for prolonged period of time. | 03-03-2016 |
20160081949 | DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST - S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage. | 03-24-2016 |
20160089346 | METHOD OF TREATMENT FOR BODY CONTOURING - Provided herein are methods involving body contouring applications including treatments to reduce subcutaneous fat. The methods include the determination of patient suitability for body contouring treatment by evaluating one or more patient assessments. In various implementations, a patient determined to be suitable for body contouring treatment is administered a composition comprising a beta-2 adrenergic receptor agonist to the region of the body comprising subcutaneous fat, such as the central abdominal or submental region. | 03-31-2016 |
20160089348 | USE OF AN S1P RECEPTOR AGONIST - The present invention relates to new uses of S1P receptor modulator or agonist such as fingolimod, for reducing or delaying the progression of cerebral atrophy. | 03-31-2016 |
20160101179 | COMPOUND FORMULATIONS OF 2-AMINO-1, 3-PROPANEDIOL COMPOUNDS - Pharmaceutical concentrate formulations comprising 2-amino-I,3-propanediol compounds, analogs thereof and salts thereof, particularly 2-amino-2-[2-(4-octylphenyl)ethyl]-propane-1,3-diol or a pharmaceutically acceptable salt thereof in an organic solvent or semi-aqueous solvent and methods for administration of the undiluted and diluted concentrate are provided. | 04-14-2016 |
20160113891 | INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ADRENALINE AND CITRIC ACID - The present invention relates to injectable pharmaceutical compositions showing improved storage stability said compositions comprising adrenaline and citric acid showing improved storage stability. | 04-28-2016 |
20160136113 | TOPICAL VASOCONSTRICTOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY - Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided. | 05-19-2016 |
20160184241 | INTRANASAL DELIVERY OF Beta2-ADRENERGIC RECEPTOR AGONISTS FOR IMPROVING COGNITION IN HUMANS WITH DOWN SYNDROME AND COMPOSITIONS THEREFOR - A method of improving cognition in a patient with Down syndrome, which entails intranasally administering one or more β2-ADR agonists or pharmaceutically-acceptable salts of either or both to the patient in an amount and with a frequency effective to improve cognition of the patient as measured contextual learning tests. | 06-30-2016 |
20160193160 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | 07-07-2016 |
20160250164 | SYSTEMIC PRO-HEMOSTATIC EFFECT OF SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON ALFA-ADRENERGIC AND/OR BETA-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH | 09-01-2016 |
20160374966 | EPINEPHRINE NANOPARTICLES, METHODS OF FABRICATION THEREOF, AND METHODS FOR USE THEREOF FOR TREATMENT OF CONDITIONS RESPONSIVE TO EPINEPHRINE - The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions. | 12-29-2016 |